@-year relapse-free survival was @ % ( @ % CI @-@ ) in the ADT plus docetaxel and estramustine group versus @ % ( @-@ ) in the ADT only group ( adjusted hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ , p = @ ) .